Rituximab Monoclonal Antibody Injection from Germany
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.15.00.11 as an immunological product containing monoclonal antibodies, put up in measured doses for retail sale in pre-filled syringes or vials.
Duty Rate — Germany → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Obtain FDA biologics license and ensure proper cold chain documentation (2-8°C) to avoid spoilage during import
• Include certificates of analysis verifying monoclonal antibody purity and biotech origin; declare as immunological product
• Avoid misclassification as general pharmaceuticals; common pitfall is insufficient proof of measured doses for retail